The management of febrile neutropenia in the posaconazole era: a new challenge?
Livio
L
Pagano
Morena
M
Caira
Manuel
M
Cuenca-Estrella
D000935:Antifungal Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D005334:Fever / Q000188:drug therapy* / Q000209:etiology; D005658:Fungi / Q000187:drug effects / Q000254:growth & development; D005690:Galactose / Q000031:analogs & derivatives; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008351:Mannans / Q000032:analysis; D009181:Mycoses / Q000150:complications / Q000209:etiology / Q000517:prevention & control*; D009503:Neutropenia / Q000150:complications / Q000209:etiology / Q000517:prevention & control*; D016133:Polymerase Chain Reaction; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D008351:Mannans; D014230:Triazoles; C012990:galactomannan; C101425:posaconazole; D005690:Galactose